Latest filing published 19 Aug 2026 for Dianthus Therapeutics, Inc. /DE/, €44k.
Filings by Simon Read span 2 companies, the busiest being Ra Pharmaceuticals, Inc. and Dianthus Therapeutics, Inc. /DE/. We count 27 filings; the first trade dates from 1 February 2019 and the latest from 19 August 2026.
No open-market purchase appears, only 15 sales worth €2.8M. Other entries cover 1 share grant and 10 option exercises. In 2026 alone, the filings show no purchases and 7 sales.
Most recently, on 19 August 2026, the filings show an option exercise worth €44k in Dianthus Therapeutics, Inc. /DE/. The median gap between a trade and its publication by SEC (Form 4) is 1 day. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
9 of 9 declarations